RHY 0.00% 11.5¢ rhythm biosciences limited

Ann: RHY Signs first ColoSTAT site for Clinical Trial - Study 7, page-4

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,058 Posts.
    lightbulb Created with Sketch. 230
    It's actually quite difficult to find out what Study 6 entails. I've had a look at the last couple of presentations and whilst they say that Study 6 is to be completed this year they don't explain what needs to be done. My impression is that study 6 is about producing the commercial test kit to be used in Study 7 (study 7 being about using that test kit on 1,000 people and comparing those results with those from FIT testing and colonoscopies). So if they are starting to line up people to be included in Study 7 it means that they are at least progressing with Study 6. But I'm guessing there.

    Also, as chiRal has pointed out , it is interesting that a unit of Sonic Healthcare is involved in Study 7. Lou Panaccio is a non-executive director of both Rhythm Biosciences and Sonic Healthcare.

    The results for Study 7 are not due out until towards the end of this calendar year so until then any share price activity will likely need to be powered by hopium.
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
(20min delay)
Last
11.5¢
Change
0.000(0.00%)
Mkt cap ! $15.41M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 5969 13.0¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 5500 1
View Market Depth
Last trade - 16.16pm 18/11/2024 (20 minute delay) ?
RHY (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.